Soluble Fibrin Monomer
Soluble fibrin monomers (SFMC) are formed during the early stages of coagulation when thrombin converts fibrinogen to fibrin, reflecting ongoing intravascular fibrin formation rather than fibrinolysis. Because SFMC appears early in the coagulation cascade, its measurement can detect active thrombogenesis before abnormalities are seen in conventional coagulation studies such as PT, APTT, or fibrinogen.
Elevated SFMC levels have been reported in acute thrombotic conditions including disseminated intravascular coagulation (DIC), venous thromboembolism, myocardial infarction, and thrombotic thrombocytopenic purpura (TTP). In cardiovascular disease, higher SFMC concentrations correlate with larger infarct size, impaired reperfusion, and poorer clinical outcomes. In patients with sepsis or malignancy, SFMC measurement improves risk stratification for thromboembolic complications. Declining values with anticoagulant or thrombolytic therapy may indicate suppression of fibrin generation.
- Early detection and risk assessment in myocardial infarction and acute thrombotic states
- As an aid in the diagnosis of prothrombotic disorders such as thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, deep venous thrombosis and pulmonary embolism
Increased in:
- Disseminated intravascular coagulation
- Deep vein thrombosis
- Pulmonary embolism
- Acute myocardial infarction
- Ischemic stroke
- Sepsis
- Metastatic cancer
- Hemolytic uremic syndrome
Decreased in:
- Advanced liver disease
- Aggressive thrombolysis therapy
- Afibrinogenemia
< or = 8 mcg/mL
Plasma, (Sodium citrate).
Stability
- Ambient: 2 hours
- Refrigerated: Unacceptable
- Frozen: 14 days
3-5 days.
- Tohoku J Exp Med. 2009 Sep;219(1):25-31. [PMID: 19713681]
- Int J Cardiol Heart Vasc. 2021 Jan 9;32:100712. [PMID: 33490365]
- Int J Cardiol Heart Vasc. 2020 Dec 24;32:100697. [PMID: 33392385]
- J Gen Intern Med. 2018 Jun;33(6):847-854. [PMID: 29569024]